The data of the Phase-I trials will be presented at the annual meeting of American Society for Clinical Oncology to be held in Chicago from June 1-5,2012
P1446A-05 exhibits high oral bio-availability, shows potent anti-proliferative activity in several human cancer cells and is efficacious in xenograft tumour models, Piramal Healthcare claimed.
The company further said: "P1446A-05 will be the second molecule in Piramal's oncology pipeline to enter Phase-II trials (conducted on a larger human sample)."
The first molecule P276 in in Phase II/III trials for multiple indications of cancer.
http://www.business-standard.com/india/news/piramal-completes-phase-i-trialsnew-cancer-molecule-/165633/on
No comments:
Post a Comment